Stay updated with breaking news from 46433010. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) had its target price raised by equities research analysts at The Goldman Sachs Group from $25.00 to $28.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “sell” rating on the stock. The Goldman Sachs Group’s price objective points to a potential downside […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has […]
Needham & Company LLC restated their buy rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $60.00 price target on the stock. A number of other research firms have also recently commented on IONS. Citigroup raised shares of Ionis […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Equities researchers at Leerink Partnrs upped their Q3 2023 EPS estimates for Ionis Pharmaceuticals in a research report issued on Monday, September 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings per share of ($0.85) for the quarter, up from their previous […]
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have received a consensus recommendation of “Hold” from the nine research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to […]